Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

KAI Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Postherpetic Neuralgia

Treatments: Drug: Lidocaine; Drug: KAI-1678; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01106716

KAI-1678-003

Details and patient eligibility

About

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption
• pain score at least 4 on 11-point numerical rating scale (0-10)
• stable doses of analgesic medications for at least 1 month"

Exclusion criteria

• diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption
• pain score at least 4 on 11-point numerical rating scale (0-10)
• stable doses of analgesic medications for at least 1 month"

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

23 participants in 3 patient groups, including a placebo group

A1: Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo

A2: KAI-1678

Experimental group

Description:

Experimental

Treatment:

Drug: KAI-1678

A3: Lidocaine

Active Comparator group

Description:

Lidocaine

Treatment:

Drug: Lidocaine